227 related articles for article (PubMed ID: 26716652)
1. Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.
Su F; Zhu S; Ruan J; Muftuoglu Y; Zhang L; Yuan Q
Oncotarget; 2016 Jan; 7(4):4142-54. PubMed ID: 26716652
[TBL] [Abstract][Full Text] [Related]
2. A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer.
Yuan Q; Cai S; Zhang X; Liu Z; Li Z; Luo X; Xiong C; Wang J; Hu J; Ruan J
Cancer Lett; 2012 Nov; 324(2):210-20. PubMed ID: 22652174
[TBL] [Abstract][Full Text] [Related]
3. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
4. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
5. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
6. A novel protoapigenone analog RY10-4 induces breast cancer MCF-7 cell death through autophagy via the Akt/mTOR pathway.
Zhang X; Wei H; Liu Z; Yuan Q; Wei A; Shi D; Yang X; Ruan J
Toxicol Appl Pharmacol; 2013 Jul; 270(2):122-8. PubMed ID: 23624174
[TBL] [Abstract][Full Text] [Related]
7. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
Han J; Ma I; Hendzel MJ; Allalunis-Turner J
Breast Cancer Res; 2009; 11(4):R57. PubMed ID: 19660128
[TBL] [Abstract][Full Text] [Related]
8. A novel protoapigenone analog RY10-4 induces apoptosis of breast cancer cells by exacerbating mitochondrial Ca
Xue P; Chen Q; Ren X; Liu D; Yang X
Toxicol Appl Pharmacol; 2021 Dec; 433():115776. PubMed ID: 34717963
[TBL] [Abstract][Full Text] [Related]
9. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.
Hsu EC; Kulp SK; Huang HL; Tu HJ; Salunke SB; Sullivan NJ; Sun D; Wicha MS; Shapiro CL; Chen CS
Neoplasia; 2015 Jun; 17(6):497-508. PubMed ID: 26152358
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling.
Yang X; Ding Y; Xiao M; Liu X; Ruan J; Xue P
Chem Biol Interact; 2017 Dec; 278():22-31. PubMed ID: 28987325
[TBL] [Abstract][Full Text] [Related]
13. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
14. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
Lee HW; Kim SJ; Choi IJ; Song J; Chun KH
Clin Exp Metastasis; 2015 Aug; 32(6):593-603. PubMed ID: 26134677
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Notch signaling pathway using γ-secretase inhibitor delivered by a low dose of Triton-X100 in cultured oral cancer cells.
Nasrin A; Hassan M; Ye P
Biochem Biophys Res Commun; 2018 Jan; 495(3):2118-2124. PubMed ID: 29253571
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
17. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
19. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
20. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
